Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP): Clinical Colorectal Cancer

Rachel P. Riechelmann, Vichien Srimuninnimit, Roberto Bordonaro, Petr Kavan, Maria Di Bartolomeo, Evaristo Maiello, Irfan Cicin, Pilar García-Alfonso, Ian Chau, Mikhail Y. Fedyanin, Carlos Fernández Martos, Mikhail Ter-Ovanesov, Marc Peeters, Yoo-Joung Ko, Suayib Yalcin, Meinolf Karthaus, Jorge Aparicio, Volker Heinemann, Pascaline Picard, Denise BuryEdward Drea, Alberto Sobrero

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The objectives of this study were to evaluate the safety profile of aflibercept and health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) provided with aflibercept access before marketing authorization. PATIENTS AND METHODS: Patients received aflibercept followed by FOLFIRI (fluorouracil, leucovorin, irinotecan) on day 1 of a 2-week cycle until disease progression, unacceptable toxicity, death, or patient/investigator decision to discontinue. Treatment-emergent adverse events (TEAEs) were evaluated, and HRQL was assessed at baseline, cycle 3, and every other cycle using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-CR29, and EuroQol 5-Dimensions 3-Levels questionnaires (NCT01571284). RESULTS: Overall, 779 adult patients with mCRC, who received ≥ 1 prior oxaliplatin-based regimen and had disease progression during or following their last administration of oxaliplatin-based chemotherapy, were enrolled. At data cutoff, all patients had discontinued treatment, mainly owing to disease progression (51.7%). The most common TEAEs of any grade were diarrhea (61.6%), hypertension (48.4%), and nausea (43.3%). The most common grade 3/4 TEAEs were hypertension (24.1%), neutropenia (23.1%), and diarrhea (15.3%). Clinically meaningful changes in HRQL were reported for all measures. Most patients either had an improvement in their HRQL scores or remained stable during the treatment period based on patient-reported outcomes. CONCLUSION: The data from this study support the tolerability of the combination of aflibercept and FOLFIRI in a setting that more closely approximates real life in patients with mCRC who failed to respond to oxaliplatin-based chemotherapy, and also suggest an improvement in HRQL.
Original languageEnglish
Pages (from-to)183
JournalClin Colorectal Cancer
Volume18
Issue number3
DOIs
Publication statusPublished - 2019

Keywords

  • Receptors
  • Vascular endothelial growth factor
  • Antiangiogenic
  • Colorectal neoplasms
  • Patient-reported outcome measures

Fingerprint Dive into the research topics of 'Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP): Clinical Colorectal Cancer'. Together they form a unique fingerprint.

  • Cite this

    Riechelmann, R. P., Srimuninnimit, V., Bordonaro, R., Kavan, P., Di Bartolomeo, M., Maiello, E., Cicin, I., García-Alfonso, P., Chau, I., Fedyanin, M. Y., Martos, C. F., Ter-Ovanesov, M., Peeters, M., Ko, Y-J., Yalcin, S., Karthaus, M., Aparicio, J., Heinemann, V., Picard, P., ... Sobrero, A. (2019). Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP): Clinical Colorectal Cancer. Clin Colorectal Cancer, 18(3), 183. https://doi.org/10.1016/j.clcc.2019.05.003